Language:
Instant News and Commentaries
2023-01-31
16:10
Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic

HONG KONG, Jan. 31, 2023 /PRNewswire/ -- In response to the infection peak season of COVID-19 in rural areas that may be brought about by people returning home during Chinese New Year, Fosun Foundation announced on 9 January 2023 the cooperation with Fosun Pharma and Genuine Biotech to donate RMB100 million worth of Azvudine tablets, the oral medication for COVID-19, helping the grassroots to weather the epidemic. As of 29 January 2023, under the campaign of "A Healthy Winter Action", a total of 173,200 bottles of Azvudine tablets have been donated to 116 counties in 19 provinces, municipalities, and autonomous regions, including Yunnan, Tibet, Xinjiang, Hainan, Anhui, Jiangxi, Ningxia, Sichuan, Chongqing, and Heilongjiang. Azvudine tablets, the first domestically developed small molecule medication for COVID-19 has helped at least 150,000 villagers get through the epidemic more safely, most of whom were seniors over 65.

Since its inception, "A Healthy Winter Action" has faced two major challenges. First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival? Second, how to accurately distribute medicines to the villagers who are in need of medicine?

While negotiating cooperation with SF Express, Fosun Foundation urgently recruited nearly a hundred employee volunteers within Fosun and its subsidiaries. Coordinating with their plan of returning home during the Spring Festival, the volunteers personally delivered medication to the donated counties.

In addition to Fosun employee volunteers, SF Express also fully supported the donation. The delivery of medication did not stop during the Spring Festival. Guo Shuai, Assistant Secretary-General and Project Director of Fosun Foundation, stayed in the office throughout the Spring Festival to make sure that the materials are dispatched to SF Express's transshipment warehouse immediately, and then delivered by air.

How to make sure that the most urgently needed villagers can receive medication in time? According to Ning Guang, Consultant of the COVID-19 Prevention and Control Expert Committee of the Rural Doctors Program and President of Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine, "Rural doctors must have medicine in their hands, and the grassroots people must receive medicine in time". Fosun Foundation first covered the 72 counties in the Rural Doctors Program which has been running for five years, and delivered as much medicine as possible to rural doctors through the health department before the Spring Festival.

On 16 January, the first batch of 600 bottles of Azvudine tablets donated to Lancang County, Yunnan Province was delivered by Zhao Zhong, a resident member of the Rural Doctors Program, to the township hospital of Lancang County, and then to the village clinics. Zhong Liping, a rural doctor in Yanyin Village, Sakai Township, received a message from villager Zhong Asuo on the morning of the fifth day of the Chinese New Year, "Thank you for the Azvudine tablets sent by Fosun Foundation before Chinese New Year. My father felt much better the next day after taking the medicine." Before taking Azvudine tablets, Zhong Asuo's 87-year-old father had fever, cough and other symptoms. When she learned that Fosun Foundation had donated to Lancang County, Zhong Liping immediately thought of distributing medicine to the elderly. Zhong Liping said, "It is this kind of feedback that makes me realize the importance of being a rural doctor."

In order to improve the diagnostic skills of rural doctors, Fosun Foundation and Shanghai Guangci Translational Medical Research Foundation jointly established an expert committee led by Chen Erzhen, Vice President of Ruijin Hospital. Medical experts from more than 20 provinces provided targeted training for rural doctors in the form of recorded courses and Q&A sessions. Relevant training has been launched on the app of Fosun Health and People's Good Doctor. So far, more than 15,000 rural doctors have received the training online. On 13 January, with the organization of the Guizhou Provincial Health Commission and Fosun Foundation, Zhang Wenhong, a member of the expert committee, Director of the National Medical Center for Infectious Diseases, and Professor of Huashan Hospital affiliated to Fudan University, conducted a special online training for rural doctors in Guizhou.

Along with the medicine, 37 care packages worth RMB150,000 were sent to the grassroots, which contained medical supplies that were in short supply at the grassroots, such as oximeters, oxygen concentrators, face masks, and nitrile gloves. These packages were donated by public welfare partners including Industrial and Commercial Bank of China, the New Social Stratum "New Philanthropy Program" under the United Front Work Department of CPC Central Committee, Shanghai Pudong Development (Group) Co., Ltd., Taiping Pension Co., Ltd., YouChange China Social Entrepreneur Foundation, Pingdingshan Volunteers Association, Chengdu Charity Federation, S.F. Express Group (Shanghai) Co., Ltd., Yeswood, Wuxi Qicheng Industrial Co., Ltd., Institute of Innovations, Tongxinhui, Xinjiang Juchen Law Firm, Jiangsu No. 33 Business Management Co., Ltd., Wuxi Yushou Medical Appliances Co., Ltd., Shanghai Tuyue Business Advisory Co., Ltd., Power Construction Corporation of China, and Shanghai Charity Foundation Xuhui District Representative Office Ningguo Temple 456 Cultural Special Fund, and benevolent enterprises of ONE Fosun such as Shede Spirits, Jinhui Liquor, Hainan Mining, and Golte.

In addition, in order to strengthen the digital capability of primary healthcare institutions, Shanghai Aitrox Technology Co. Ltd., a subsidiary of Fosun, donated digital imaging systems, digital ultrasound systems and refined operation services to primary township hospitals, covering 10 township hospitals by the end of April this year, with the first batch of donations amounting to approximately RMB5 million.

On 28 January 2023, the first day of work, the project team resumed regular meetings twice a day. At the regular meeting that night, Chen Qiyu, Co-CEO of Fosun International, said, "We have completed half of the RMB100 million medicine donation, and reached 2/3 of the goal of donating to 180 counties. We must continue to race against the virus and prepare for the next wave of infection peaks. For example, we must cover at least another 20 counties in the Tibet Autonomous Region; we must focus on protecting the elderly in cities below the third tier and in rural nursing homes. The donation of about 400,000 bottles of Azvudine tablets worth RMB100 million jointly initiated by Fosun and Genuine Biotech has been considered to be the largest public welfare donation of medicine in recent years. We hope play its due role in the revitalization of Chinese rural areas and the construction of a healthy China."

Information Provided by PR Newswire [Disclaimer]
10:42
17萬瓶阿茲夫定春節不停運,助農村平穩渡疫

香港2023年1月31日 /美通社/ -- 為應對返鄉潮可能帶來的農村感染高峰,上海復星公益基金會(下稱「復星基金會」)於2023年1月9日宣佈,聯合復星醫藥、真實生物,為廣大農村地區捐贈人民幣1億元的新冠口服藥阿茲夫定,助力基層更好渡疫過年。至1月29日,「鄉村暖冬計劃」已為雲南、西藏、新疆、海南、安徽、江西、寧夏、四川、重慶、黑龍江等19個省、市、自治區116個縣捐贈阿茲夫定173,200瓶,這些首個國產新冠小分子藥至少幫助15萬村民更安全地渡疫,其中大部分為65歲以上的老人。

從啟動開始,「鄉村暖冬計劃」就面臨兩大挑戰:一、如何在春運高峰期間將物資運往基層?二、如何將藥品精準送達基層缺醫少藥的村民手裏?

在和順豐速遞洽談合作的同時,復星基金會在復星及旗下企業內部緊急招募到近百名員工志願者,結合自己的春節返鄉計劃將藥品「人肉」背到受捐縣。

除了復星員工志願者的助力,捐贈也得到順豐速遞的全力支持,藥品的發送在春節期間也沒有停頓,復星基金會助理秘書長、項目總監郭帥整個春節期間守在辦公室,確保能第一時間將物資送到順豐的轉運倉再通過空運發出。

如何確保最急需的村民能及時用上藥?按鄉村醫生項目新冠防治專家委員會顧問、上海交通大學醫學院附屬瑞金醫院院長寧光院士的要求:「一定要讓鄉村醫生手上有藥,一定要最基層百姓能及時用藥」,復星基金會首先覆蓋已經開展了5年的72個鄉村醫生項目縣,通過衛健部門在節前就將藥品盡可能送到鄉村醫生手裏。

1月16日,捐贈至雲南瀾滄縣的首批600瓶阿茲夫定,在鄉村醫生項目駐點隊員趙重的運送下,派送至瀾滄縣各鄉鎮衛生院,再發到村衛生室。酒井鄉巖因村的鄉村醫生鍾麗萍,在大年初五的早晨收到村民鍾阿所發來的信息:「謝謝復星基金會年前送來的阿茲夫定,我爸爸吃完後第二天就好了很多。」鍾阿所的父親今年87歲,在服用到阿茲夫定前兩天,出現了發燒、咳嗽等症狀,當接到復星基金會向瀾滄縣捐贈的消息時,鍾麗萍第一時間就想到要給老人派藥。鍾麗萍說:「正是這樣的反饋,讓我感受到作為一名村醫的價值。」

為提升村醫的診斷能力,復星基金會和上海廣慈轉化醫學研究發展基金會合作成立了由瑞金醫院副院長陳爾真領銜的專家委員會,來自20多省的醫學專家以錄製課程、視頻答疑等形式為村醫診療提供有針對性的指導,相關課程上線復星健康、人民好醫生客戶端,至今有超過15,000名村醫上線學習。1月13日,在貴州省衛健委和復星基金會的組織下,專家委員會成員、國家傳染病醫學中心主任、復旦大學附屬華山醫院張文宏教授還為貴州的鄉村醫生在線開展了專場培訓。

隨著藥品送到基層的還有37個價值人民幣15萬的愛心包,內含血氧儀、製氧機、口罩、丁腈手套等基層緊缺的醫療物資。這些愛心包由中國工商銀行、中央統戰部新的社會階層人士新善工程、上海浦東發展(集團)有限公司、太平養老保險股份有限公司、友成企業家鄉村發展基金會、平頂山市志願者協會、成都市慈善總會、順豐速運集團(上海)速運有限公司、源氏木語、無錫棋成實業有限公司、浙江求是創新研究院、同心薈、新疆巨臣律師事務所、江蘇三十三號商業管理有限公司、無錫市宇壽醫療器械有限公司、上海途越商務諮詢有限公司、中國電建、上海市慈善基金會徐滙區代表處寧國禪寺四五六文化專項基金等公益夥伴及「復星一家」愛心企業舍得酒業、金徽酒、海南礦業、高地物業等出資捐贈。

此外,為加強基層醫療機構的數字化能力,復星旗下上海杏脈信息科技有限公司為基層鄉鎮衛生院捐贈數智影像系統、數智超聲系統及提供精細化運營服務,今年4月底前覆蓋10個受捐縣各一個鄉鎮衛生院,首批捐款金額約人民幣500萬元。

1月28日,開工首日,項目團隊恢復每天兩次的例會。在當晚的例會上,復星國際聯席CEO陳啟宇表示:「人民幣1億元的藥品捐贈目前我們完成了一半,捐贈180個縣的目標完成了2/3,我們要繼續和病毒賽跑,也要為下一波感染高峰做好準備。比如西藏自治區至少要再覆蓋20個縣;要重點守護三線以下城市及鄉村養老院裡的老人。這次復星和真實生物共同發起的人民幣1億元約40萬瓶阿茲夫定捐贈,可以說是新中國成立以來規模最大的一次藥品捐贈公益行動,我們要讓它為中國鄉村振興和健康中國的建設發揮應有的作用。」

Information Provided by PR Newswire [Disclaimer]
2023-01-30
14:19
An Auspicious Start to the Year of the Rabbit: Fosun Sees Boom in Various Businesses During the Spring Festival Golden Week

HONG KONG, Jan. 30, 2023 /PRNewswire/ -- During the Spring Festival Golden Week this year, benefiting from the recovery of domestic consumption, various operating indicators of the business segments like Happiness and Health of Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) surged, setting an auspicious start to the Year of the Rabbit.

During the Spring Festival holiday from Chinese New Year's Eve to the sixth day of Chinese New Year (21-27 January 2023), the occupancy rate of Fosun Tourism Group's Club Med resorts in China continued to rise, the average occupancy rate of Club Med Lijiang for six nights reached 95%, and the average occupancy rate of Club Med Guilin exceeded 90%, both Club Med Joyview Anji and Club Med Joyview Qiandao Lake achieved a high occupancy rate of over 95%. In addition, the average occupancy rate of the ski resorts in Beidahu, Yabuli and Changbaishan exceeded 85%.

As one of the preferred destinations for domestic travel, Atlantis Sanya, a benchmark project of Fosun Tourism Group, has continued to be in high demand since the beginning of 2023. During the New Year holiday period, the average occupancy rate reached 97.4%, the total reception was about 37,000 person-times, and the business volume exceeded the pre-pandemic level. It is expected that Atlantis Sanya will record close to 100% occupancy for 22 consecutive days from 9 January to 31 January 2023 and record more than 97% occupancy in January, a record high since its opening.

It is worth mentioning that, thanks to the steady recovery of consumer travel confidence, the mid- and long-term bookings of Fosun Tourism's major resorts have recently increased significantly, and subsequent businesses have continued to improve. "The Spring Festival holiday has just ended, and many consumers are already planning to travel during the Labor Day holiday in May. For this reason, we believe that the auspicious start of the Spring Festival will continue," the relevant person in charge of Fosun Tourism said.

During the Spring Festival holiday, the 2023 Yuyuan Garden Lantern Festival being held in the Grand Yuyuan in Shanghai was frequently featured on WeChat Moments. This year's Yuyuan Garden Lantern Festival is inspired by "The Classic of Mountains and Seas", a major source of Chinese mythology. With modern intangible cultural heritage, multi-media, AR and other technologies, the Yuyuan Garden Lantern Festival presents "a magic adventure of mountains and sea" in Downtown Shanghai and has become a main attraction in Shanghai.

The popularity of the Yuyuan Garden Lantern Festival has also effectively boosted consumption. From the opening on 26 December 2022 to 27 January 2023, Yuyuan Tourist Mart attracted a total of 2.33 million visits, representing a year-on-year increase of 20%. Sales during the Spring Festival holiday have also returned to pre-pandemic level. The sales of many brands such as Laomiao, Yayi, Lubolang, Nanxiang Steamed Bun Restaurant, and Shanghai Classical Restaurant rebounded significantly. It is particularly worth mentioning that, according to statistics, among the visitors to the Yuyuan Garden Lantern Festival, the proportion of young people born in the 90s, 95s and 00s has increased significantly, and the consumer group has become significantly younger compared to the pre-pandemic period.

Located right next to the Yuyuan Garden, the Bund Finance Center (BFC) has also attracted many visits. A series of activities such as the BFC Fireside Party, NICE Rabbit Garden Party, and the BFC Ice Skating Rink have ignited consumption enthusiasm. BFC's sales revenue increased by 27% and passenger flow increased by 21%, compared to the seven-day Spring Festival holiday last year.

Regarding the Health segment, as the COMIRNATY® bivalent vaccine was officially registered as a drug/product (biological product) in Hong Kong SAR and was approved as a regular imported vaccine in Macao SAR, Mainland Chinese residents visiting Hong Kong SAR and Macao SAR to receive COMIRNATY® vaccination has recently attracted great attention, the number of inquiries and appointments have increased significantly during the Spring Festival holiday.

On Chinese New Year's Eve, Fosun Pharma and a number of enterprises including Genuine Biotech announced joint expansion of production to 24-hour full production during the Spring Festival holiday to make every effort to ensure the stable supply and production of Azvudine tablets. During the Spring Festival holiday, all member hospitals of Fosun Health continued to provide diagnosis and treatment services, and Internet hospitals also continued to provide 24-hour online emergency services to patients, ensuring the supply of Azvudine tablets, the oral medication for COVID-19. The overall online sales during the Spring Festival holiday increased by 244% year-on-year.

It is reported that in response to the infection peak season for COVID-19 during the Spring Festival holiday, Fosun Health launched a series of live broadcasts on health, and joined hands with Fosun Foundation to hire five consultants including Chen Saijuan, Ning Guang, and Fan Jia, and 38 well-known experts in China including Chen Erzhen, Zhang Shuyang, and Zhang Wenhong, helping primary medical institutions with COVID-19 prevention and control work and providing services such as online training, prescription assistance, and consultation to rural doctors on Fosun Health's "Cloud Guardian" platform.

On 10 January, Guo Guangchang, Chairman of Fosun International expressed his steadfast optimism on China's economy in the program "Dialogue" of the CCTV-2 Finance Channel. He said, "In 2023, I believe that the family-oriented consumer sector that Fosun is engaged in will gradually see an increase in demand, and our offline retail and tourism businesses will be among the first to snap back."

The Spring Festival Golden Week offers a glimpse of the economic situation of the whole year. Market analysts believe that the outstanding performance of Fosun's businesses during the Spring Festival holiday signals an upward development trend in 2023. Driven by the strategy of reinforcing its positioning as "a global innovation-driven consumer group", Fosun will usher in an important period of development opportunities.

Recently, international rating agency S&P Global Ratings, and investment banks including Morgan Stanley and Daiwa Capital Markets issued reports expressing their optimistic about Fosun. With the optimization of China's epidemic prevention and control measures and Fosun's continuous focus on the core businesses in the family-oriented consumer sector, it is expected that Fosun's businesses will see a bounce back soon.

Information Provided by PR Newswire [Disclaimer]
14:19
兔年開門紅 復星多個板塊業務春節黃金周表現亮眼

香港2023年1月30日 /美通社/ -- 今年春節黃金周期間,受益於國內消費復甦,復星國際有限公司(簡稱「復星國際」或「公司」)(香港聯交所股份代號:00656)旗下快樂、健康等板塊多項經營指標實現快速提升,迎來兔年開門紅。

除夕至初六(1月21日-27日)春節假期,復星旅文Club Med地中海俱樂部中國區度假村入住率持續走高,麗江度假村六晚平均入住率達95%,桂林度假村平均入住率超九成,Joyview安吉與千島湖度假村均實現95%以上的高入住率。此外,北大壺、亞布力、長白山三座滑雪度假村平均入住率也超過85%。

作為國內出遊首選地之一,復星旅文標桿性項目三亞·亞特蘭蒂斯2023年開年以來持續火爆,元旦期間平均入住率達97.4%,總接待人次達約3.7萬人次,營業額超越疫情前水平,1月9日至31日預計連續22天接近滿房,1月全月入住率將超97%,創開業以來新高。

值得一提的是,得益於消費者出遊信心的穩步恢復,近期復星旅文各大度假村中長期的預訂量顯著提升,後續業務呈現持續走強趨勢。「春節假期剛結束,不少消費者已在規劃五一出遊,這讓我們更加相信春節的開門紅將僅僅是一個開始。」復星旅文相關負責人表示。

春節期間,在上海大豫園片區內舉辦的2023年豫園燈會持續刷屏朋友圈。今年的豫園燈會主題聚焦《山海經》這一中國神話巨製,用現代非遺燈彩方式演繹,多媒體、實景結合AR增強現實等技術加持,在上海鬧市呈現了「山海奇豫記」的奇幻世界,成為滬上最人氣滿滿的打卡地。

燈會的火爆也有力帶動了商圈消費。自2022年12月26日亮燈至2023年1月27日,豫園商城合計接待客流233萬人次,同比上升20%,春節期間的銷售額也已恢復至疫情前水平,老廟、亞一、綠波廊、南翔饅頭店、上海老飯店等眾多品牌銷售情況均明顯反彈。尤為值得一提的是,根據統計數據,前來賞燈的客群中,90後、95後以及00後的年輕群體佔比大幅提升,客群結構較疫情前呈現出顯著的年輕化態勢。

緊鄰豫園的BFC外灘金融中心人氣同樣旺盛。外灘楓徑圍爐大會、NICE兔遊園會、外灘冬日冰場等一系列活動點燃消費熱情,同比去年春節七天長假, BFC銷售額增長27%,客流增長21%。

在大健康業務領域,隨著復必泰二價疫苗相繼在中國香港獲正式註冊為藥品/製品(生物製品),及在中國澳門獲批准為常規進口疫苗,近期內地居民赴港澳接種復必泰受到高度關注,春節期間諮詢量、預約量顯著提升。

春節前夕,復星醫藥與真實生物等多家企業宣佈聯合擴產,24小時滿負荷生產,節假日不停工,全力以赴做好阿茲夫定片的保供保產。春節期間,復星健康旗下各成員醫院均推行「無假日」診療服務,互聯網醫院也持續為患者提供24小時在線急診服務,保供新冠口服藥阿茲夫定片,春節期間線上整體銷售額同比增長244%。

為應對春節新冠感染高峰,復星健康還開展了系列健康直播,並攜手復星基金會,聘請陳賽娟、寧光、樊嘉等五位院士顧問,陳爾真、張抒揚、張文宏等38位全國知名專家,助力基層醫療機構的新冠防治工作,通過復星健康「雲守護平台」向廣大村醫群體提供線上培訓、輔助開方、專家諮詢等服務。

1月10日 ,復星國際董事長郭廣昌在中央電視台《對話》欄目中展望了2023經濟發展新動能,表達了堅定看好中國經濟的信心。他表示,「2023年,我相信復星所從事的家庭消費產業,將逐步迎來需求的提升,相信我們線下的商業和文旅板塊將首先迎來快速的反彈。」

春節黃金周,是透視全年經濟的一扇窗口。市場分析人士認為,春節期間復星業務的亮眼表現,傳遞出2023年發展態勢向好的積極信號。在「創新驅動的全球家庭消費產業集團」戰略驅動下,復星將迎來重要的發展機遇期。

近期,標普、摩根士丹利、大和資本等國際評級機構和投行,也紛紛發表報告看好復星,認為隨著疫情防控政策優化,以及復星不斷聚焦家庭消費主業,未來業績回彈可期。

Information Provided by PR Newswire [Disclaimer]
2023-01-27
09:00
Fosun International's 2021 Annual Report Wins Gold Award at the 2022 International ARC Awards

HONG KONG, Jan. 27, 2023 /PRNewswire/ -- Winners of the 36th International ARC Awards have been announcement. The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022 International ARC Awards. The award commends Fosun International's annual report for its distinctive theme, clear business and development strategies, sufficient content and forward-looking perspective, and excellent concept and layout design.

Hailed as the "Academy Awards of annual reports", the International ARC Awards is the world's most prestigious competition honoring excellence in annual reports. Some of the elements to be considered in the judging of the annual reports include theme of the annual report, chairman's letter, the company's business development and strategy, cover and interior design, presentation of corporate information, expression of financial data, and how well the spirit of the organization is communicated. Judges come from around the globe to participate on the ARC jury panels. Preliminary judging is carried out by panels of judges representing leaders in the fields of investments, writing, design and photography. Final judging is made by presidents, CEOs and other senior executives of corporations, agencies, and design firms. Winners are granted Honors, Bronze, Silver, and Gold awards.

In addition to Fosun International, CK Hutchison Holdings and NWS Holdings also won awards in the Traditional Annual Report - Diversified Business category of the 2022 International ARC Awards. Winners of the International ARC Awards this year include many well-known large Chinese and foreign companies, including CLP Holdings, Airport Authority Hong Kong, Hang Seng Bank, Industrial and Commercial Bank of China, China Construction Bank, New World Development, China Telecom, China Mobile, Alibaba, etc.

The awards demonstrates the market's recognition of Fosun's business strategy

The theme of Fosun International's 2021 annual report was "Sustain Resilience and Accumulate Capabilities to Empower the Future". In 2022, despite the volatile global epidemic situation and the headwinds of anti-globalization, Fosun is still a firm practitioner of globalization. In 2022, COMIRNATY® COVID-19 mRNA vaccine continued to provide an anti-epidemic barrier for Hong Kong SAR, Macao SAR and the Taiwan region; Club Med opened new resorts; Lanvin Group was successfully listed on the New York Stock Exchange. In the face of uncertainties, Fosun remained committed to technology and innovation in order to weather market cycles. HANQUYOU, independently developed by Henlius, was successfully launched in Australia after entering the European Union market; the registration application in the Chinese Mainland for the new indication of Yi Kai Da, China's first CAR-T cell therapy was officially accepted.

In recent years, although the global market has been going through different stages of the economic cycle, Fosun has remained committed to its core businesses. Looking forward to 2023, Fosun has mapped out the future direction for development: Fosun will reinforce its positioning as "a global innovation-driven consumer group", focus on its core businesses strategically around the consumption needs of global families, and strengthen the two core growth engines of globalization and innovation. Since the beginning of the year, Fosun's main businesses centering on household consumption, such as Health, Happiness, and Wealth, have shown signs of strong recovery and its forward-looking efforts in the anti-epidemic field have gradually borne fruit.

The two flagships of Fosun's Happiness segment, Fosun Tourism Group and Yuyuan have shown strong signs of recovery. According to market sources, when the domestic tourism industry suffered a huge setback in 2022, Fosun Tourism Group still stood firm to build global presence and opened seven new Club Med resorts throughout the year. Club Med's global bookings in the first half of 2023 have greatly exceeded the same period in 2019 before the pandemic. During the 2023 New Year holiday period, Atlantis Sanya, FOLIDAY Town Lijiang and other businesses in China all performed better than their respective pre-pandemic levels, and many Club Med resorts in China recorded close to 100% occupancy. During the 2023 New Year holiday period, the 2023 Yuyuan Garden Lantern Festival in the Grand Yuyuan attracted a large number of tourists. It is expected that the Spring Festival will further unleash consumption vitality.

Fosun's anti-epidemic "vaccine and drug" products have attracted great attention from the market. The self-paid vaccination service of COMIRNATY® bivalent vaccine was launched in Hong Kong SAR and vaccination is open to people including Mainland Chinese residents starting from 6 January 2023. After the self-paid vaccination service of COMIRNATY® monovalent COVID-19 mRNA vaccine has opened for non-local residents in Macau SAR last year, it is informed that the COMIRNATY® bivalent vaccine became a regular imported vaccine in Macao SAR on 20 January 2023, and people in need may receive a booster dose with prescription. As regards Azvudine tablets, the oral medication for COVID-19, it is now included in the medical insurance scheme in 31 provinces, autonomous regions, and direct-administered municipalities across the country. It is rapidly expanding its coverage in hospitals and is now available in major healthcare institutions across the country, including secondary hospitals, tertiary hospitals, and primary healthcare institutions. The accessibility of Azvudine tablets has been greatly enhanced, helping the vast areas build a barrier against severe cases.

The market is optimistic about Fosun's strategies of accelerating its strategic transformation and focusing on household consumption sectors. A number of investment banks, including Morgan Stanley, Citi, Goldman Sachs and Nomura have published reports and assigned Fosun International an "Overweight" or "Buy" rating.

International ARC Awards

Established in 1987, the International ARC Awards is the world's renowned competition honoring excellence in annual reports. Hailed as the "Academy Awards of annual reports", the International ARC Awards is globally recognized for its openness and fairness, providing a platform for the highest standards in the annual report industry. Every year, it attracts more than a thousand companies from different industries, government agencies, non-profit organizations as well as other organizations around the world to enter the competition.

Information Provided by PR Newswire [Disclaimer]
09:00
復星國際2021年報榮獲「2022年國際ARC年報大獎」金獎

香港2023年1月27日 /美通社/ -- 第36屆International ARC Awards(「國際ARC年報大獎」)獎項評審結果揭曉,復星國際有限公司(簡稱「復星國際」或「公司」)(香港聯交所股份代號:00656)的2021年報榮獲「2022年國際ARC年報大獎」的「傳統年報」金獎,表彰復星國際年報主題鮮明、業務及發展策略清晰、內容論述和前瞻性充足、設計意念及版式設計鋪排均具可觀性。

「國際ARC年報大獎」為全球享負盛名的國際年報大賽,被譽為「年報界奧斯卡」。年報主要評選內容包括:年報主題、董事長的信及公司業務發展和策略闡述、封面及內頁設計、公司信息及財務數據的表達,以及年報對於企業精神的傳遞程度等。評委來自世界各地,初審評審團由投資市場、寫作、設計和攝影之行業領導者組成,最終評審團則由公司、機構和設計公司的總裁、首席執行官和其他高級管理人員組成。獎項分別設金銀銅及榮譽獎。

與復星國際一同躋身「2022年國際ARC年報大獎」的「傳統年報-多元業務」 獎項,還有長江和記實業及新創建集團。今年獲得國際ARC年報大獎的其他類別的公司還包括許多知名的中外大型企業,包括中電控股、香港機場管理局、恒生銀行、中國工商銀行、中國建設銀行、新世界控股、中國電訊、中國移動、阿里巴巴等。

獎項彰顯市場認同復星業務戰略

復星國際去年年報主題為「堅韌致遠,厚積薄發」。2022年,儘管全球疫情持續反覆、全球化遭遇逆風寒流,復星依然是全球化的堅定踐行者,並展現出非凡的韌勁與抗風險能力。復必泰®疫苗為港澳台持續提供防疫屏障、Club Med又有一批新的度假村開業、復朗集團成功在紐交所上市。面對不確定性,復星依然堅持科創的價值足以穿越周期,復宏漢霖自主開發的「漢曲優」繼登陸歐盟後又成功在澳大利亞上市;國內首款CAR-T細胞治療產品奕凱達的新增新適應症於中國境內的上市註冊申請獲得正式受理。

近年來,儘管全球市場正經歷經濟周期,復星堅定聚焦核心業務。展望2023年,復星明確未來發展方向:錨定「創新驅動的全球家庭消費產業集團」定位,圍繞全球家庭消費需求,戰略上更加聚焦主業,同時加碼全球化和創新兩大核心增長引擎。開年以來,復星旗下圍繞家庭消費的健康、快樂、富足等主業板塊已顯現強勁復蘇跡象,在抗疫領域的前瞻性佈局也逐步迎來業績兌現。

復星快樂板塊下的復星旅文及豫園股份各項業務已呈現明顯復蘇態勢。據了解,在國內文旅行業受到重挫的2022年,復星旅文仍堅定推進全球佈局,全年新開7家Club Med度假村。2023年上半年,Club Med全球市場預定額已大幅超過新冠疫情前2019年同期。而2023元旦期間,三亞·亞特蘭蒂斯、麗江復遊城等多項國內業務均超越疫情前水平,Club Med多個中國度假村接近滿房。元旦期間,大豫園片區內2023年豫園燈會吸引大量遊客打卡刷屏,預計春節還將迎來新的一波消費高潮。

復星在抗疫領域布局的「一苗一藥」 業務進展迅速。自今年1月6日起,復必泰®二價疫苗在中國香港開展自費接種服務,開放了包括內地居民在內的人士接種。繼去年非澳居民自費接種復必泰®原始株疫苗在中國澳門開放後,2023年1月20日,復必泰®二價疫苗接獲通知在中國澳門成為常規進口疫苗,可於處方下安排有需要人士的加強劑接種。同時,新冠口服藥阿茲夫定片,已在全國31個省、自治區、直轄市完成醫保掛網,並正加快全國醫院終端鋪貨,現已覆蓋全國各地主要醫療機構,包括二級以上醫院和基層醫療衛生機構等,大幅提升了終端可及性,助力廣大地區築起「防重症」保護墻。

市場對於復星加快自身戰略轉型,聚焦「家庭消費」產業主賽道的策略明顯是看好的。多家投行包括大摩、花旗、高盛、野村等均發表報告給予復星國際「增持」或「買入」評級。

「國際ARC年報大獎」(International ARC Awards)

International ARC Awards 從1987年開始舉辦,是全球享負盛名表彰優秀年報的評審比賽,被譽為「年報界奧斯卡」,由美國獨立機構 MerComm, Inc. 主辦。International ARC Awards 因公開、公正而在全球聞名,並為年報業界定下最高的標準,每年吸引逾千家來自全球不同行業的企業、政府部門、非牟利機構及團體參賽。

Information Provided by PR Newswire [Disclaimer]
2023-01-26
20:24
Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has cleared for the previously announced collaboration and license agreement between Akeso and Summit Therapeutics (the "Summit") for the breakthrough bispecific antibody, Ivonescimab (PD-1/VEGF). Akeso had received the first tranche of the upfront payment of US$300 million.

The first tranche of the upfront payment of US$300 million comprised US$274.9 million in cash and US$25.1 million in the form of 10,000,000 consideration shares allotted and issued by the Summit for US$2.51 per consideration share ( the "Consideration Shares Payment"), which was determined based on the volume-weighted average price of the shares of the Summit of 5 trading days prior to and after the date of the License Agreement in accordance with the License Agreement. The second tranche of the upfront payment of US$200 million will be paid within 90 days from the signing date of the License Agreement. Dr. XIA Yu, Chairwoman, Executive Director, CEO and President of Akeso, had been appointed to the board of directors of the Summit under the License Agreement. Akeso opted to hold Summit shares, and Dr. XIA Yu accepted the appointment as a director of the Summit to further strengthen the cooperation with the Summit.

Information Provided by PR Newswire [Disclaimer]
14:59
Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed by The Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2022. This year, Fosun International was accredited with the Platinum Award by The Asset for the first time after being presented with the Gold Award for four consecutive years. The Asset also awarded Fosun International Best Investor Relations Team Award.

Organized by The Asset, a renowned Asian financial magazine, The Asset Corporate Awards that has been running for many years is one of the world's leading environmental, social and governance (ESG) awards. This year, Fosun International was accredited with the Platinum Award at The Asset ESG Corporate Awards 2022, reflecting the magazine's recognition of Fosun's outstanding performance in various fields including financial performance, management, corporate governance, social and environmental responsibility, investor relations, information disclosure and corporate communication. Other recipients of the Platinum Award include Agricultural Bank of China, Bank of China (Hong Kong), China Overseas Land and Investment, China Unicom, Kerry Properties, Shui On Land, Sino Land, etc.

Fosun International's ESG performance has been highly recognized by rating agencies

In recent years, global investors and stakeholders have attached increasing importance to the ESG performance of enterprises. Fosun International has been continuing to promote the development of ESG and has achieved impressive results. Its MSCI ESG rating was AA and the Hang Seng Sustainability rating was A. Fosun International has been selected as a constituent stock of Hang Seng ESG 50 Index (top 50 large-to-mid cap) for two consecutive years and it has been included as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index for three consecutive years, which includes 87 Hong Kong-listed companies with the most outstanding performance in corporate sustainability (top 20% of the Hang Seng Composite Index constituent stocks). All these affirm Fosun's ESG achievements and the global recognition of Fosun's ESG efforts.

Fosun's two treasures, "drug + vaccine" highlight the Group's innovative achievements and social responsibility contributions to the fight against the pandemic

The technology innovation capabilities that Fosun accumulated over the years have continued to bear fruit. On 19 December 2022, COMIRNATY®, including the monovalent COVID-19 mRNA vaccine (BNT162b2) and the bivalent vaccine which can protect against the Omicron variant, was officially registered as a drug/product (biological product) in Hong Kong SAR. The self-paid vaccination service of COMIRNATY® bivalent vaccine was launched in Hong Kong SAR and vaccination is open to people including Mainland Chinese residents starting from 6 January 2023. After the self-paid vaccination service of COMIRNATY® monovalent COVID-19 mRNA vaccine has opened for non-local residents in Macau SAR last year, the COMIRNATY® bivalent vaccine was approved by Macao SAR as a regular imported vaccine on 20 January 2023, and people in need may receive a booster dose with prescription. As regards Azvudine, the oral medication for COVID-19, it is now included in the medical insurance scheme in 31 provinces, autonomous regions, and direct-administered municipalities across the country. In addition to tertiary hospitals and secondary hospitals, Azvudine has gradually covered grassroots medical institutions in many provinces. The accessibility of Azvudine has been greatly enhanced, helping the vast areas build a barrier against severe cases.

Improving communication in the global capital market, Fosun's long-term strategy has been recognized by investors

In recent years, the global market has been going through different stages of the economic cycle. Fosun has focused on its core businesses, deepened innovation and globalization, and maintained long-term effective communication with the capital market and investors. In 2022, Fosun overcame challenges such as the pandemic, and completed 420 domestic and overseas investor roadshows in 11 countries and regions around the world to actively communicate with global investors. Fosun has received high recognition and support from investors for its long-term strategy and corporate value. The Asset awarded Fosun International the "Best Investor Relations Team Award", which demonstrates the market's recognition of Fosun International's corporate management and operations, information disclosure, transparency, and communication with stakeholders, and affirms Fosun's long-term investment value.

Despite the headwinds of anti-globalization in 2022, Fosun is still a firm practitioner of globalization. In 2022, COMIRNATY® COVID-19 mRNA vaccine continued to provide an anti-epidemic barrier for Hong Kong SAR, Macao SAR and the Taiwan region; Club Med opened new resorts; Lanvin Group was successfully listed on the New York Stock Exchange. In the face of uncertainties, Fosun remained committed to technology and innovation in order to weather market cycles. HANQUYOU, independently developed by Henlius, was successfully launched in Australia after entering the European Union market; the registration application in the Chinese Mainland for the new indication of Yi Kai Da, China's first CAR-T cell therapy was officially accepted. Fosun attaches great importance to its development. No matter how policies and markets change, Fosun will always devote its best efforts.

Fosun is actively making strategic adjustments in the face of the constant changes in the macro environment and revealed the future development direction of Fosun: Fosun will reinforce its positioning as "a global innovation-driven consumer group", focus on its core businesses strategically around the consumption needs of global families, and strengthen the two core growth engines of globalization and innovation. The market is optimistic about Fosun's strategies of accelerating its strategic transformation and focusing on household consumption sectors. A number of investment banks, including Morgan Stanley, Citi, Goldman Sachs and Nomura, have published reports and assigned Fosun International an "Overweight" or "Buy" rating.

Market analyst believes that as the "one-off" negative impact of the external environment clears, Fosun's continuous focus on the family-oriented consumer sector will usher in an important period of opportunity for business rebound in 2023. Since the beginning of the year, Fosun's main businesses centering on household consumption, such as Health, Happiness, and Wealth, have shown signs of strong recovery and Fosun's forward-looking efforts in the anti-epidemic field have gradually borne fruit.

The two flagships of Fosun's Happiness segment, Fosun Tourism Group and Yuyuan, and other businesses have shown strong signs of recovery. According to market sources, when the domestic tourism industry suffered a huge setback in 2022, Fosun Tourism Group still stood firm to build global presence and opened seven new Club Med resorts throughout the year. Club Med's global bookings in the first half of 2023 have greatly exceeded the same period in 2019 before the pandemic. During the 2023 New Year holiday period, Atlantis Sanya, FOLIDAY Town Lijiang and other businesses in China all performed better than their respective pre-pandemic levels, and many Club Med resorts in China recorded close to 100% occupancy. During the 2023 New Year holiday period, the 2023 Yuyuan Garden Lantern Festival in the Grand Yuyuan attracted a large number of tourists. It is expected that the Spring Festival will further unleash consumption vitality.

Fosun's solid fundamentals and recovery potential have been widely recognized by financial institutions and investors 

On 16 January 2023, Shanghai Fosun High Technology (Group) Co., Ltd. ("Fosun High Technology"), the domestic operating entity of Fosun International, received a RMB12 billion syndicated loan from eight domestic banks. This is the largest private enterprise loan led by five major state-owned banks in cooperation with policy banks and joint-stock banks since the Central Economic Work Conference explicitly proposed in December 2022 to encourage and support the development of the private economy and private enterprises. Moreover, Fosun High Technology successfully completed bookbuilding for the RMB1 billion super & short-term commercial paper on 13 January 2023.

According to a report published by S&P Global Ratings, Fosun International's total debt at the holding company level could drop by 15%-25% in 2023 as the company continues to dispose assets and pay down matured bonds, thereby further improving its liquidity. According to incomplete statistics, Fosun's return of capital from its asset reduction in 2022 has reached tens of billions of yuan. Morgan Stanley also issued a report commenting that Fosun's syndicated loan can further improve its liquidity, significantly helping lift market confidence in Fosun's stability. Looking ahead, the reopening of China will help boost fundamentals, especially in businesses such as tourism, retail, and investment.

2022 marked the 30th anniversary of Fosun's establishment. Standing at the new starting point of 30 years of establishment, Fosun will continue to strengthen its core businesses, deepen innovation and globalization. Fosun will continue to join hands with customers, partners, investors and all parties in the society to forge ahead and continue to uphold its original aspiration of "Contribution to Society", so as to actively promote the sustainable development of ESG to fulfil Fosun's mission of "Creating Happier Lives for Families Worldwide".

About The Asset Corporate Awards

Organized by The Asset, a renowned Asian financial magazine, The Asset Corporate Awards is one of the world's leading and longest-running awards. The judging committee, which composes of professional investors and analysts, assesses the overall performance including financial performance, corporate governance, social and environmental responsibility, information disclosure and corporate communication of listed companies in the Asia-Pacific region through online questionnaire submissions made by the participating companies, then follow by obtaining feedback from the investor community and analysts through interview, in order to select and award the winning companies based on the overall score. It has a strong influence in Asia and the international capital markets.

Information Provided by PR Newswire [Disclaimer]
14:54
復星國際榮獲《財資》雜誌頒發「2022年財資ESG企業大獎鉑金獎」

香港2023年1月26日 /美通社/ -- 復星國際有限公司(簡稱「復星國際」或「公司」)(香港聯交所股份代號:00656)近日接獲亞太區知名金融財經行業雜誌《財資》的通知,獲該雜誌授予「2022年財資ESG企業大獎鉑金獎」(The Asset ESG Corporate Awards 2022 – Platinum Award)。這是復星國際連續四年榮獲財資ESG企業大獎金獎後,進一步攀升一級,並首次獲該雜誌授予ESG企業大獎鉑金獎。《財資》同時授予復星國際「最佳投資者關係獎」。

《財資》旗下「環境、社會及管治」(ESG)企業大獎的評選歷時多年,是亞太地區處於領先地位的 ESG獎項之一。本次復星國際獲評《財資》ESG企業大獎鉑金獎,表彰公司在財務表現、管理、企業管治、社會責任、環境保護、投資者關係、信息披露及企業傳播等範疇的卓越表現。其他同時獲得「2022年財資ESG企業大獎鉑金獎」的公司包括中國農業銀行、中國銀行(香港)、中國海外發展、中國聯通、嘉里建設、瑞安房地產、信和置業等。

復星國際ESG表現獲評級機構高度認可

近年,全球投資者愈來愈重視企業在ESG方面的績效,復星國際一直也在持續推動ESG方面的工作,並取得不俗的成果。MSCI ESG評級為AA,恒生可持續發展評級為A,並連續兩年入選恒生ESG 50指數(中大型股Top 50)成份股,連續三年入選恒生可持續發展企業基準指數成份股,該指數包含在企業可持續發展方面表現最卓越的87家香港上市公司(可持續發展評級表現Top 20%)。這些成績均印證了復星在ESG領域的建樹和全球廣泛的認可。

復星兩寶+,彰顯公司創新成果及助力抗擊疫情的社會責任貢獻

復星長期積累的科創能力也持續結出碩果。2022年12月19日,復必泰®(包括原始株和覆蓋奧密克戎的二價疫苗)獲正式註冊為中國香港藥品/製品(生物製品)。自2023年1月6日起,復必泰®二價疫苗在中國香港開展自費接種服務,開放了包括內地居民在內的人士接種。繼去年非澳居民自費接種復必泰®原始株疫苗在中國澳門開放後,2023年1月20日,復必泰®二價疫苗也獲中國澳門批准為常規進口疫苗,可於處方下安排有需要人士的加強劑接種。同時,新冠口服藥阿茲夫定,已在全國31個省、自治區、直轄市完成醫保掛網,除三、二級醫院外,已逐步覆蓋至多個省份基層醫療機構,大幅提升了終端可及性,助力廣大地區築起「防重症」保護牆。

完善全球資本市場溝通,投資者認同復星長遠戰略

近年來全球市場正經歷經濟周期,復星聚焦核心業務,深化創新及全球化佈局,始終保持與資本市場及投資者的長期有效溝通。2022年克服疫情等複雜因素,在全球11個國家及地區完成420場海內外投資人路演,實現與全球投資人的充份溝通,並獲得投資者對復星的長遠戰略和企業價值的高度認同和支持。《財資》授予復星國際「最佳投資者關係獎」,佐證市場對復星國際在業務管理運營、信息披露、透明度、與利益相關者溝通等水平的高度認可,亦是對公司長期投資價值的肯定。

2022年,儘管全球化遭遇逆風寒流,復星依然是全球化的堅定踐行者,復必泰®疫苗為港澳台持續提供防疫屏障、Club Med又有一批新的度假村開業、復朗集團成功在紐交所上市。面對不確定性,復星依然堅持科創的價值足以穿越周期,復宏漢霖自主開發的「漢曲優」繼登陸歐盟後又成功在澳大利亞上市;國內首款CAR-T細胞治療產品奕凱達的新增新適應症於中國境內的上市註冊申請獲得正式受理。復星最重要的事情還是企業自身的發展,不管政策、市場如何變化,都要把事情做到極致。

在外部宏觀環境不斷變化的情況下,復星正主動進行戰略調整,進一步明確了復星未來的發展方向:錨定「創新驅動的全球家庭消費產業集團」定位,圍繞全球家庭消費需求,戰略上更加聚焦主業,同時加碼全球化和創新兩大核心增長引擎。市場對於復星加快自身戰略轉型,聚焦「家庭消費」產業主賽道的策略明顯是看好的。多家投行包括大摩、花旗、高盛、野村等均發表報告給予復星國際 「增持」或「買入」評級。

市場分析人士認為,隨著外部環境「一過性」影響出清,2023年,復星不斷聚焦的家庭消費主業將迎來回彈的重要機遇期。開年以來,復星旗下圍繞家庭消費的健康、快樂、富足等主業板塊已顯現強勁復蘇跡象,在抗疫領域的前瞻性布局也逐步迎來業績兌現。

事實上,復星快樂板塊兩大旗艦——復星旅文及豫園股份各項業務已呈現明顯復蘇態勢。據了解,在國內文旅行業受到重挫的2022年,復星旅文仍堅定推進全球佈局,全年新開七家Club Med度假村。2023年上半年,Club Med全球市場預訂額已大幅超過新冠疫情前2019年同期。而2023元旦期間,三亞·亞特蘭蒂斯、麗江復遊城等多項國內業務均超越疫情前水平,Club Med多個中國度假村接近滿房。元旦期間,大豫園片區內2023年豫園燈會吸引大量遊客打卡刷屏,預計春節還將迎來新的一波消費高潮。

復星紮實的基本面及業績蘇潛力獲金融機構及大行認可

2023年1月16日,復星國際在境內的運營實體上海復星高科技(集團)有限公司(簡稱「復星高科」)獲得八家國內銀行人民幣120億元銀團貸款。這是2022年12月中央經濟工作會議明確提出「鼓勵支持民營經濟和民營企業發展壯大」以來,由五大國有銀行牽頭,聯合政策性銀行、股份制銀行完成的最大一筆民營企業貸款。此外,復星高科還於2023年1月13日成功完成了人民幣10億元超短期融資券簿記發行。

標普發表的報告指出,隨著復星國際持續處置資產及償還到期債券,2023年復星國際集團層面總債務有望下降15%至25%,進一步改善流動性。據不完全統計,2022年復星國際資產減持已實現資金回籠達數百億元。摩根士丹利報告稱,銀團貸款落地,可進一步改善公司的流動性,極大提升市場對復星穩定發展的信心。展望未來,中國的重新開放將有助於基本面提振,特別是旅遊、零售和投資等業務。

2022年是復星成立三十周年。站在三十年的新起點上,復星將持續深耕產業,深化創新及全球化佈局,與客戶、合作夥伴、投資者、社會各方攜手並進,並將繼續秉承「助天下」的初心,積極推動全球ESG可持續發展,踐行「讓全球家庭生活更幸福」的使命。

《財資》雜年度企業大獎介紹

《財資》雜誌主辦的年度企業大獎評選頗具權威,評審委員會由專業投資者及財經分析師組成,通過問卷調研、機構投資者投票、以及專業投資者的意見徵詢等方式,全面評估亞太地區上市企業在財務業績、企業治理、社會責任、環境保護、信息披露與傳播、投資者關係等各方面的表現,從中嚴謹篩選出表現優秀的企業予以嘉獎和肯定,其評比在亞洲乃至國際金融市場享有較高影響力和權威性。

Information Provided by PR Newswire [Disclaimer]
2023-01-20
18:16
Global Review 2022: GWM Expands Its Global Layout, Empowered by Forest Ecosystem

BAODING, China, Jan. 20, 2023 /PRNewswire/ -- On January 16, a documentary featuring GWM went on air, depicting the advantages of GWM in hybrid, power batteries, intelligentization and its global strategic layout.

In 2022, GWM moved forward the globalization strategy steadily through the Forest Ecosystem even under the continuous impact of factors challenging the global automobile market, such as supply chain shortage and the epidemic.

Global Review 2022: GWM Expands Its Global Layout, Empowered by Forest Ecosystem
Global Review 2022: GWM Expands Its Global Layout, Empowered by Forest Ecosystem

The Forest Ecosystem, centered on the new energy and intelligence, has a unique systematic advantage. Mr. Jack Wei, Chairman of GWM, mentioned in the documentary that GWM upholds the R&D concept of "precise investment and continuous pursuit of leading technology".  In 2022, GWM has continued to increase the investment of technology R&D in the Forest Ecosystem. The total investment in the first three quarters exceeded CNY 8.5 billion, up over 64% YoY.

The technology in this ecosystem that GWM accumulated for years has continued to bear fruit. GWM has built a product matrix of new energy products, including HEV, PHEV, and EV to meet the differentiated requirements of global markets. In 2022, HAVAL, a SUV brand of GWM, officially released the new energy strategy, and introduced Hybrid models in several markets, such as Australia, Chile, Pakistan, South Africa, Thailand, and Brazil, and has been highly recognized by the markets and consumers.

Furthermore, GWM has been expanding its layout in the luxury new energy vehicle market. GWM WEY, a high-end intelligent new energy brand, has launched Coffee 01 and Coffee 02 with a combination of luxury and advanced technology. These vehicles promoted GWM to develop the European new energy market. The WEY Coffee 01 equipped with the HPilot system, a cutting-edge smart driving assistance system, has won the five-star Euro NCAP safety rating. GWM TANK, the premium off-road SUV brand, has launched the TANK300 HEV and TANK500 HEV/PHEV, which lead the electrification transformation of the industry.

GWM also has gained a systematic advantage in hydrogen energy by leveraging forest ecosystem. It currently has established an integrated supply chain ecosystem, which includes hydrogen "production-storage-transportation-refueling-application". As for the development of hydrogen energy, GWM has invested CNY 2.5 billion in total in hydrogen fuel battery vehicles to put it into mass production.

GWM boasts the most demanding criteria for the quality and technology of its products. It already has core technology reserves and supply chain capabilities in the new energy and intelligence fields, and has kept ahead through significant cutting-edge investments, Jack Wei mentioned.

He also said that the new energy and intelligent technology have brought enormous growth potential for GWM. With "ONE GWM" as the core strategy, the company will increase technology R&D investment in the future to accelerate the transformation into a global intelligent technology company.

Information Provided by PR Newswire [Disclaimer]